BFS
ALNY icon

Bradley Foster & Sargent’s Alnylam Pharmaceuticals ALNY Stock Holding History

Bradley Foster & Sargent’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$407K Buy
1,351
+148
+12% +$44.6K 0.01% 436
2026
Q1 		$398K Buy
1,203
+502
+72% +$171K 0.01% 420
2025
Q4 		$279K Buy
701
+81
+13% +$35.8K ﹤0.01% 474
2025
Q3 		$283K Buy
+620
New +$252K ﹤0.01% 471
2021
Q4 		– Sell
-5,223
Closed -$986K – 449
2021
Q3 		$986K Hold
5,223
– – 0.02% 233
2021
Q2 		$885K Sell
5,223
-1,622
-24% -$238K 0.02% 244
2021
Q1 		$966K Sell
6,845
-3,453
-34% -$520K 0.02% 228
2020
Q4 		$1.34M Buy
+10,298
New +$1.38M 0.04% 201
2018
Q3 		– Sell
-3,175
Closed -$313K – 368
2018
Q2 		$313K Sell
3,175
-2,120
-40% -$210K 0.01% 314
2018
Q1 		$631K Sell
5,295
-2,940
-36% -$379K 0.02% 252
2017
Q4 		$1.05M Hold
8,235
– – 0.04% 215
2017
Q3 		$968K Buy
8,235
+4,120
+100% +$352K 0.04% 217
2017
Q2 		$328K Hold
4,115
– – 0.01% 298
2017
Q1 		$211K Buy
+4,115
New +$190K 0.01% 324
2016
Q4 		– Sell
-4,115
Closed -$279K – 343
2016
Q3 		$279K Hold
4,115
– – 0.01% 303
2016
Q2 		$228K Buy
+4,115
New +$259K 0.01% 313
2015
Q1 		– Sell
-2,500
Closed -$242K – 356
2014
Q4 		$242K Buy
+2,500
New +$232K 0.01% 312
2014
Q3 		– Sell
-3,500
Closed -$221K – 354
2014
Q2 		$221K Buy
+3,500
New +$208K 0.01% 322
2013
Q4 		– Sell
-3,400
Closed -$218K – 344
2013
Q3 		$218K Buy
+3,400
New +$169K 0.01% 312

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Bradley Foster & Sargent's ALNY Position: Q2 2026 in Review

Bradley Foster & Sargent increased its Alnylam Pharmaceuticals (ALNY) stake by 12% in Q2 2026, buying an estimated $44.6K and bringing the position to 1,351 shares worth $407K. The position accounts for 0.01% of the portfolio, ranked #436.

Bradley Foster & Sargent first reported a position in ALNY in Q3 2013 and has held it in 19 quarters since. The position peaked at $1.34M in Q4 2020. 785 funds tracked by Wall St. Rank hold ALNY as of Q2 2026.

  • Bradley Foster & Sargent held 1,351 shares of Alnylam Pharmaceuticals worth $407K as of Q2 2026.
  • Bradley Foster & Sargent bought 148 Alnylam Pharmaceuticals shares in Q2 2026, an estimated $44.6K.
  • Alnylam Pharmaceuticals made up 0.01% of Bradley Foster & Sargent's portfolio in Q2 2026, its #436 holding.
  • Bradley Foster & Sargent first reported a position in Alnylam Pharmaceuticals in Q3 2013 and has held it in 19 quarters since.
  • Bradley Foster & Sargent's Alnylam Pharmaceuticals position peaked at $1.34M in Q4 2020.
  • 785 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2026.

Based on Bradley Foster & Sargent's 13F filing for Q2 2026, filed 14 Aug 2026.